Thymosin Alpha-1 vs VIP
Thymosin alpha-1 is a 28-amino-acid peptide derived from prothymosin alpha and originally isolated from thymic tissue, registered as a prescription immunomodulator in a number of countries and studied in more than thirty controlled human trials. Vasoactive intestinal peptide is also 28 amino acids long, but belongs to the secretin-glucagon family and signals through the class B receptors VPAC1 and VPAC2; its synthetic form, aviptadil, has been tested in respiratory failure, sarcoidosis and erectile dysfunction. Unusually for a pair of this kind, direct evidence exists. Between 1986 and 1996 a pharmacology group in Seville published a series of radioligand-binding and adenylate cyclase experiments in which both peptides were tested in the same preparations, and reported that thymosin alpha-1 competes weakly at VIP receptors. That work is entirely in vitro and decades old. Nothing since has compared the two in an animal model or in people, and their clinical literatures address unrelated indications.
They have been compared directly.
Four published experiments tested both peptides in the same assay system. Calvo and colleagues reported in 1986 that thymosin alpha-1 inhibited the specific binding of iodinated VIP to rat blood mononuclear cells and liver plasma membranes, but was two to nearly four orders of magnitude less potent than VIP itself, and stimulated adenylate cyclase only weakly; they described it as a possible partial VIP agonist. A 1989 follow-up in rat intestinal epithelial cells placed thymosin alpha-1 last in an affinity series behind VIP, PHI and secretin. A 1990 study from an independent group in Durham reproduced that ranking on the solubilised hepatic VIP receptor. Pozo and colleagues extended the work in 1996 across rat and mouse peritoneal macrophages and rat blood and spleen lymphocytes, again finding weak displacement and weak adenylyl cyclase stimulation, and concluded that thymosin alpha-1 should be regarded as the lowest partial agonist of the VIP family and a VIP receptor antagonist with weak intrinsic activity. All four are cell-free or cell-culture pharmacology studies; none administered either peptide to an animal or to a person, and no study has compared their clinical effects.
The 9 studies that tested both
- 01In vitro1986
Interaction of thymic peptide thymosin alpha 1 with vasoactive intestinal peptide (VIP) receptors.
Calvo JR, et al. · Bioscience Reports · rat blood mononuclear cells and rat liver plasma membranes; competition binding against iodinated VIP plus adenylate cyclase activity
Thymosin alpha-1 inhibited the specific binding of iodinated VIP to both preparations, but was reported to be 160-fold less potent than VIP in blood mononuclear cells and 6250-fold less potent in liver plasma membranes. Its stimulation of adenylate cyclase was weak, with an efficacy of roughly a quarter that of native VIP in both systems. The authors concluded that thymosin alpha-1 may behave as a partial VIP agonist in the rat.
- 02In vitro1989
Interaction of thymic peptide thymosin alpha 1 with VIP receptors in rat intestinal epithelial cells: comparison with PHI and secretin.
Calvo JR, et al. · General Pharmacology · rat intestinal epithelial cells; competition binding against iodinated VIP and cyclic AMP production, with PHI and secretin as comparator peptides
Thymosin alpha-1 inhibited specific binding of iodinated VIP to rat intestinal epithelial cells and was reported to be 1500-fold less potent than VIP. Its stimulation of cyclic AMP production was weak. Across the peptides tested the order of affinity ran VIP, then PHI, then secretin, then thymosin alpha-1.
- 03In vitro1990
Vasoactive intestinal peptide receptor on liver plasma membranes: solubilization and cross-linking.
Nguyen TD, Kaiser LM · Peptides · rat liver plasma membranes; digitonin solubilisation of the VIP receptor, radioligand binding and chemical cross-linking
The solubilised hepatic VIP receptor retained high affinity and specificity for VIP, and its binding preference ranked VIP above PHI, above secretin, above thymosin alpha-1, matching the order observed on intact membranes. Cross-linking identified a band consistent with the native receptor in both solubilised and non-solubilised preparations.
- 04In vitro1996
Thymosin alpha 1 interacts with the VIP receptor-effector system in rat and mouse immunocompetent cells.
Pozo D, et al. · Immunopharmacology · rat and mouse peritoneal macrophages, rat peripheral blood lymphocytes and rat spleen lymphocytes; iodinated VIP binding and adenylyl cyclase assays with helodermin, PHI, secretin and glucagon as comparators
Thymosin alpha-1 inhibited iodinated VIP binding in every cell type examined, with a potency roughly one thousand to seventeen hundred times lower than native VIP, and stimulated adenylyl cyclase far less efficiently than VIP. The authors reported structural and physicochemical similarities between the N-terminal portion of thymosin alpha-1 and members of the VIP family, and described thymosin alpha-1 as the lowest partial agonist of that family and a VIP receptor antagonist with weak intrinsic activity.
- 05Review1999
Molecular biological ontogenesis of the thymic reticulo-epithelial cell network during the organization of the cellular microenvironment.
Bodey B, et al. · In Vivo · narrative review of thymic reticulo-epithelial cell biology and intrathymic T-cell selection
The review described thymosin alpha-1 and thymopoietin as thymic hormones produced immunocytochemically by the same reticulo-epithelial cells, and listed vasoactive intestinal peptide among the pituitary hormones and neuropeptides secreted by that network, together with receptors for those mediators. Neither peptide was administered, and the two were discussed as separate products of a shared cellular microenvironment.
- 06Review2000
The role of the reticulo-epithelial (RE) cell network in the immuno-neuroendocrine regulation of intrathymic lymphopoiesis.
Bodey B, et al. · Anticancer Research · narrative review of immuno-neuroendocrine regulation of intrathymic lymphopoiesis
The review reported that thymulin, thymosin alpha-1 and thymopoietin were detected immunocytochemically in thymic reticulo-epithelial cells, and again listed vasoactive intestinal peptide among the neuropeptides co-produced by those cells. The authors treated the co-existence of thymic hormone and neuropeptide secretion by a single cell type as the point of interest; no comparison of the two peptides was attempted.
- 07Review2019
Inhaled Biologicals for the Treatment of Cystic Fibrosis.
Sala V, Murabito A, Ghigo A · Recent Patents on Inflammation & Allergy Drug Discovery · patent and literature review of inhaled peptide-based drugs and delivery carriers for cystic fibrosis
The review covered vasoactive intestinal peptide and thymosin alpha-1 as separate candidate inhaled peptides for cystic fibrosis, citing work in which VIP rescued trafficking of the F508del CFTR protein and restored protein function, and describing thymosin alpha-1 as a proposed anti-inflammatory agent and CFTR modulator alongside a later report that it did not correct F508del CFTR in airway epithelia. No comparative experiment was carried out.
- 08Review2020
Challenges for Drug Repurposing in the COVID-19 Pandemic Era.
Sultana J, et al. · Frontiers in Pharmacology · review of drugs proposed for repurposing in COVID-19, indexed against registered clinical trials
The review catalogued aviptadil, described as a vasoactive intestinal polypeptide analogue and listed among candidates for COVID-19-induced acute respiratory distress syndrome on the basis of a proposed effect on pulmonary oedema, and separately listed thymalfasin as having been administered to individuals with end-stage renal disease with the stated aim of reducing infection rate and severity. Both appeared as repurposing candidates in a table rather than as compared interventions.
- 09Review2025
Aging and Thymosin Alpha-1.
Simonova MA, et al. · International Journal of Molecular Sciences · narrative review of thymosin alpha-1 in thymic involution and immunosenescence
The review summarised thymosin alpha-1 as a thymic peptide hormone reported to stimulate T-cell differentiation, enhance thymic output and modulate dendritic cell and macrophage activity, and listed vasoactive intestinal peptide among the neuropeptides expressed by thymus cells. The authors stated that further research was needed to validate long-term efficacy and safety in geriatric use.
Side by side.
| Thymosin Alpha-1 | VIP | |
|---|---|---|
| Evidence maturity | Approved drug | Clinical |
| Studies cited here | 16 | 15 |
| Published 2023 or later | 11 | 9 |
| Newest paper | 2026 | 2026 |
| Sequence and origin | A 28-amino-acid peptide derived from prothymosin alpha, originally isolated from thymic tissue and detected immunocytochemically in thymic reticulo-epithelial cells. | A 28-amino-acid neuropeptide of the secretin-glucagon family, distributed in enteric, pulmonary and central neurons including the suprachiasmatic nucleus. Its synthetic form is designated aviptadil. |
| Mechanism as described in the literature | Acts largely through Toll-like receptor signalling on dendritic cells and monocytes, influencing T-cell differentiation, thymic output and cytokine balance. | Signals through the class B G protein-coupled receptors VPAC1 and VPAC2 with cyclic AMP as the principal second messenger, with described roles in pulmonary vasodilation, surfactant regulation, suppression of pro-inflammatory cytokine release, regulatory T cell induction and circadian pacemaking. |
| Relationship established between the two molecules | Radioligand work from 1986 to 1996 placed thymosin alpha-1 at the bottom of the VIP family affinity series, behind helodermin, PHI and secretin, and characterised it as a weak partial agonist and a receptor antagonist with low intrinsic activity. | VIP was the reference ligand in every one of those experiments. Its reported affinity for the receptors studied was between roughly one hundred and several thousand times higher than that of thymosin alpha-1, depending on the tissue. |
| Size of the evidence base | Sixteen verified studies in this library, of which nine are human clinical trials and five are systematic reviews or meta-analyses; one animal study and one review complete the set. | Fifteen verified studies, of which six are human clinical and one is a systematic review, the remainder being narrative reviews, animal in vivo work and in vitro receptor pharmacology. |
| Best-characterised finding | Immune reconstitution and infection-related endpoints in chronic hepatitis B, sepsis and oncology adjuvant settings, where small and mid-sized randomised trials have repeatedly reported benefit that larger trials have not confirmed. | Receptor pharmacology of VPAC1 and VPAC2, documented to the level of an IUPHAR review, together with pulmonary vasodilation and circadian synchrony of clock neurons in animal models. |
| Human data | More than thirty controlled trials. The largest and most rigorous, the phase 3 TESTS study in sepsis, found no mortality benefit, and the pooled meta-analytic signal weakens when analysis is restricted to high-quality multicentre trials. The same pattern recurs in pancreatitis and hepatitis B cirrhosis. | Randomised trials of intravenous aviptadil in COVID-19-associated respiratory failure, the largest of which, TESICO, found no significant clinical benefit; a 2025 systematic review of ARDS trials reported a pooled survival odds ratio of 1.01. An aviptadil-phentolamine intracavernosal combination is an established second-line agent in erectile dysfunction practice. |
| Regulatory status | Registered as a prescription immunomodulator in a number of countries, principally for chronic hepatitis B and as an adjuvant in sepsis and oncology. Not approved by the FDA or EMA. | Aviptadil is marketed in some jurisdictions in combination with phentolamine for erectile dysfunction. No approval exists for acute respiratory distress syndrome, sarcoidosis or pulmonary arterial hypertension. |
| Basis of most marketing claims | Extrapolation from prescription immunomodulation in hepatitis B and oncology to general immune support and healthy ageing, an indication for which no controlled human trial has been published. | Extrapolation from receptor pharmacology and small inhaled-route or open-label studies, against a randomised record in respiratory failure that was negative and a native peptide with a very short plasma half-life. |
And what it does not.
This is one of the few pairs in the catalogue with genuine head-to-head data, and the data say something narrower than the phrase suggests. Four in vitro studies established that thymosin alpha-1 binds VIP receptors, at a potency between roughly one hundred and six thousand times below VIP itself, and stimulates the associated cyclase weakly. That is a statement about molecular cross-reactivity in rodent membranes and cultured cells, not about comparative clinical effect, and the most recent of those experiments was published in 1996. Away from the receptor bench the two literatures barely touch. Thymosin alpha-1 has a large randomised trial record in infection and oncology whose largest studies were null, and no controlled trial as a longevity intervention. VIP has strong receptor characterisation, a negative randomised record in respiratory failure, and an approved combination product only in erectile dysfunction. Neither has controlled human evidence for the general immune-support or wellness uses that prompt the comparison, and no study has ever administered both to an animal or a person.
Common questions.
- Has any study given both thymosin alpha-1 and VIP to the same animals or patients?
No. The four studies that engage both peptides are radioligand binding and cyclase assays carried out on isolated membranes and cultured cells from rats and mice. They measured how well thymosin alpha-1 displaced labelled VIP from its receptors and how strongly each peptide activated the downstream enzyme. No experiment has administered both compounds within a single in vivo design, and no clinical trial has compared them on any shared endpoint.
- What does it mean that thymosin alpha-1 was described as a partial agonist of the VIP family?
It means that in the assays reported, thymosin alpha-1 occupied VIP receptors and produced a smaller downstream signal than VIP itself. The 1996 study in immunocompetent cells went further and characterised it as a VIP receptor antagonist with weak intrinsic activity, placing it below helodermin, PHI and secretin in the affinity series. Because the effect required far higher concentrations than VIP, the authors framed it as a structural relationship rather than a physiologically dominant one.
- Why does the receptor literature stop in the 1990s?
The four binding studies came from a small number of laboratories, principally a group in Seville, and the line of work was not continued after 1996. Later research on both peptides moved in different directions: thymosin alpha-1 towards Toll-like receptor signalling and randomised trials in infection and oncology, VIP towards VPAC receptor pharmacology, aviptadil trials in respiratory failure, and circadian neuroscience. No group has revisited the cross-reactivity question with modern receptor methods.
- Do the two peptides appear together in any recent publication?
Yes, but only as separate entries in reviews. A 2019 review of inhaled biologicals for cystic fibrosis discussed each as a candidate inhaled peptide, and a 2020 review of COVID-19 drug repurposing listed aviptadil and thymalfasin among proposed agents. Reviews of thymic reticulo-epithelial biology note that the same cells produce thymosin alpha-1 and secrete vasoactive intestinal peptide. None of these publications administered either compound or compared them.
- Which of the two has the stronger randomised trial record?
Thymosin alpha-1 has the larger volume, with more than thirty controlled trials across hepatitis B, sepsis, pancreatitis, COVID-19 and oncology. Volume is not the same as confirmation: the phase 3 TESTS study found no mortality benefit in sepsis, and pooled effects shrink when analysis is limited to high-quality multicentre trials. VIP has fewer trials, and its largest, TESICO, was also negative. Neither record supports the general immune or wellness claims made for the compounds.
For research purposes only. Not for human consumption, diagnosis, treatment, or prevention of any condition. Nothing on this page is medical advice, and no comparison here should be read as a recommendation of either compound.